dr. brander on targeted agents in cll
Published 5 years ago • 224 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
0:31
copy of dr. brander on targeted agents in cll
-
2:12
dr. brander on the safety and efficacy of ibrutinib/venetoclax in cll
-
2:00
dr. brander discusses the frontline treatment of cll
-
1:36
dr. brander on the treatment landscape for patients with high-risk cll
-
1:15
dr. bhat on the role of targeted therapies in cll
-
1:50
dr. barrientos discusses promising agents in cll
-
0:51
dr. seymour on role of ibrutinib in cll
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:12
dr. mato on immunotherapy options in cll
-
0:40
from chemotherapy towards targeted therapies in cll
-
1:53
dr. kahl on frontline btk inhibitor selection in cll
-
35:46
cll patient expert q&a: dr. danielle brander
-
5:33
combining targeted therapies in cll
-
1:27
frontline therapies for treatment naive cll patients
-
7:42
combining and sequencing new agents in chronic lymphocytic leukemia
-
1:50
targeted therapy in cll in 2022 and in the future
-
2:05
the latest on targeted therapies in cll
-
2:01
dr. adrian wiestner discusses ibrutinib/bendamustine/rituximab in the phase iii helios trial
-
0:57
dr. byrd on alacabrutinib's mechanism of action in cll